Log in

NASDAQ:TRVITrevi Therapeutics Competitors & Alternatives

$6.98
-0.63 (-8.28 %)
(As of 07/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.70
Now: $6.98
$8.49
50-Day Range
$2.66
MA: $4.54
$7.62
52-Week Range
$1.33
Now: $6.98
$8.49
Volume139,300 shs
Average Volume73,476 shs
Market Capitalization$124.55 million
P/E RatioN/A
Dividend YieldN/A
Beta0.58

Competitors

Trevi Therapeutics (NASDAQ:TRVI) Vs. NLTX, SNDX, URGN, ATHX, MIRM, and CLVS

Should you be buying TRVI stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Trevi Therapeutics, including Neoleukin Therapeutics (NLTX), Syndax Pharmaceuticals (SNDX), Urogen Pharma (URGN), Athersys (ATHX), Mirum Pharmaceuticals (MIRM), and Clovis Oncology (CLVS).

Neoleukin Therapeutics (NASDAQ:NLTX) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.

Profitability

This table compares Neoleukin Therapeutics and Trevi Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neoleukin TherapeuticsN/A-26.95%-25.39%
Trevi TherapeuticsN/A-51.74%-46.55%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Neoleukin Therapeutics and Trevi Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neoleukin Therapeutics00603.00
Trevi Therapeutics00103.00

Neoleukin Therapeutics currently has a consensus price target of $21.50, indicating a potential upside of 53.57%. Trevi Therapeutics has a consensus price target of $18.00, indicating a potential upside of 157.88%. Given Trevi Therapeutics' higher probable upside, analysts plainly believe Trevi Therapeutics is more favorable than Neoleukin Therapeutics.

Institutional & Insider Ownership

59.3% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 78.3% of Trevi Therapeutics shares are held by institutional investors. 7.1% of Neoleukin Therapeutics shares are held by company insiders. Comparatively, 47.3% of Trevi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Neoleukin Therapeutics and Trevi Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neoleukin Therapeutics$25 million21.49$-69,440,000.00($0.75)-18.67
Trevi TherapeuticsN/AN/A$-26,050,000.00($2.28)-3.06

Trevi Therapeutics has lower revenue, but higher earnings than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Trevi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Neoleukin Therapeutics has a beta of -4.41, meaning that its share price is 541% less volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500.

Summary

Trevi Therapeutics beats Neoleukin Therapeutics on 6 of the 11 factors compared between the two stocks.

Syndax Pharmaceuticals (NASDAQ:SNDX) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.

Profitability

This table compares Syndax Pharmaceuticals and Trevi Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Syndax Pharmaceuticals-4,013.65%-132.06%-73.26%
Trevi TherapeuticsN/A-51.74%-46.55%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Syndax Pharmaceuticals and Trevi Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Syndax Pharmaceuticals02702.78
Trevi Therapeutics00103.00

Syndax Pharmaceuticals currently has a consensus price target of $21.3750, indicating a potential upside of 46.60%. Trevi Therapeutics has a consensus price target of $18.00, indicating a potential upside of 157.88%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Trevi Therapeutics is more favorable than Syndax Pharmaceuticals.

Institutional & Insider Ownership

57.5% of Syndax Pharmaceuticals shares are held by institutional investors. Comparatively, 78.3% of Trevi Therapeutics shares are held by institutional investors. 9.5% of Syndax Pharmaceuticals shares are held by company insiders. Comparatively, 47.3% of Trevi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Syndax Pharmaceuticals and Trevi Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syndax Pharmaceuticals$1.52 million346.23$-56,050,000.00($1.84)-7.92
Trevi TherapeuticsN/AN/A$-26,050,000.00($2.28)-3.06

Trevi Therapeutics has lower revenue, but higher earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Trevi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Syndax Pharmaceuticals has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500.

Summary

Trevi Therapeutics beats Syndax Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

Urogen Pharma (NASDAQ:URGN) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Institutional and Insider Ownership

64.4% of Urogen Pharma shares are owned by institutional investors. Comparatively, 78.3% of Trevi Therapeutics shares are owned by institutional investors. 12.0% of Urogen Pharma shares are owned by company insiders. Comparatively, 47.3% of Trevi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Urogen Pharma and Trevi Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Urogen PharmaN/A-63.41%-58.23%
Trevi TherapeuticsN/A-51.74%-46.55%

Analyst Ratings

This is a summary of recent recommendations for Urogen Pharma and Trevi Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Urogen Pharma02402.67
Trevi Therapeutics00103.00

Urogen Pharma presently has a consensus price target of $45.20, suggesting a potential upside of 78.23%. Trevi Therapeutics has a consensus price target of $18.00, suggesting a potential upside of 157.88%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Trevi Therapeutics is more favorable than Urogen Pharma.

Volatility and Risk

Urogen Pharma has a beta of 1.72, meaning that its share price is 72% more volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500.

Valuation and Earnings

This table compares Urogen Pharma and Trevi Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Urogen Pharma$20,000.0026,497.40$-105,150,000.00($5.12)-4.95
Trevi TherapeuticsN/AN/A$-26,050,000.00($2.28)-3.06

Trevi Therapeutics has lower revenue, but higher earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Trevi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Trevi Therapeutics beats Urogen Pharma on 9 of the 12 factors compared between the two stocks.

Athersys (NASDAQ:ATHX) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Institutional and Insider Ownership

17.3% of Athersys shares are owned by institutional investors. Comparatively, 78.3% of Trevi Therapeutics shares are owned by institutional investors. 12.6% of Athersys shares are owned by company insiders. Comparatively, 47.3% of Trevi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Athersys and Trevi Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AthersysN/A-184.41%-104.23%
Trevi TherapeuticsN/A-51.74%-46.55%

Analyst Ratings

This is a summary of recent recommendations for Athersys and Trevi Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Athersys00403.00
Trevi Therapeutics00103.00

Athersys presently has a consensus price target of $9.00, suggesting a potential upside of 234.57%. Trevi Therapeutics has a consensus price target of $18.00, suggesting a potential upside of 157.88%. Given Athersys' higher probable upside, equities research analysts clearly believe Athersys is more favorable than Trevi Therapeutics.

Volatility and Risk

Athersys has a beta of -1.7, meaning that its share price is 270% less volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500.

Valuation and Earnings

This table compares Athersys and Trevi Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Athersys$5.63 million93.88$-44,580,000.00($0.29)-9.28
Trevi TherapeuticsN/AN/A$-26,050,000.00($2.28)-3.06

Trevi Therapeutics has lower revenue, but higher earnings than Athersys. Athersys is trading at a lower price-to-earnings ratio than Trevi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Trevi Therapeutics beats Athersys on 7 of the 11 factors compared between the two stocks.

Mirum Pharmaceuticals (NASDAQ:MIRM) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Institutional and Insider Ownership

73.3% of Mirum Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.3% of Trevi Therapeutics shares are owned by institutional investors. 45.5% of Mirum Pharmaceuticals shares are owned by company insiders. Comparatively, 47.3% of Trevi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Mirum Pharmaceuticals and Trevi Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mirum PharmaceuticalsN/A-60.55%-41.38%
Trevi TherapeuticsN/A-51.74%-46.55%

Analyst Ratings

This is a summary of recent recommendations for Mirum Pharmaceuticals and Trevi Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mirum Pharmaceuticals00603.00
Trevi Therapeutics00103.00

Mirum Pharmaceuticals presently has a consensus price target of $27.3333, suggesting a potential upside of 35.65%. Trevi Therapeutics has a consensus price target of $18.00, suggesting a potential upside of 157.88%. Given Trevi Therapeutics' higher probable upside, analysts clearly believe Trevi Therapeutics is more favorable than Mirum Pharmaceuticals.

Valuation and Earnings

This table compares Mirum Pharmaceuticals and Trevi Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mirum PharmaceuticalsN/AN/A$-52,550,000.00($4.58)-4.40
Trevi TherapeuticsN/AN/A$-26,050,000.00($2.28)-3.06

Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Trevi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Trevi Therapeutics beats Mirum Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

Clovis Oncology (NASDAQ:CLVS) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Volatility and Risk

Clovis Oncology has a beta of 2.51, meaning that its share price is 151% more volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500.

Profitability

This table compares Clovis Oncology and Trevi Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Clovis Oncology-271.13%N/A-62.01%
Trevi TherapeuticsN/A-51.74%-46.55%

Institutional and Insider Ownership

44.2% of Clovis Oncology shares are owned by institutional investors. Comparatively, 78.3% of Trevi Therapeutics shares are owned by institutional investors. 6.6% of Clovis Oncology shares are owned by company insiders. Comparatively, 47.3% of Trevi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Clovis Oncology and Trevi Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clovis Oncology$143.01 million3.51$-400,420,000.00($7.60)-0.86
Trevi TherapeuticsN/AN/A$-26,050,000.00($2.28)-3.06

Trevi Therapeutics has lower revenue, but higher earnings than Clovis Oncology. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Clovis Oncology, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Clovis Oncology and Trevi Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Clovis Oncology25502.25
Trevi Therapeutics00103.00

Clovis Oncology presently has a consensus price target of $15.1429, suggesting a potential upside of 132.07%. Trevi Therapeutics has a consensus price target of $18.00, suggesting a potential upside of 157.88%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Trevi Therapeutics is more favorable than Clovis Oncology.

Summary

Trevi Therapeutics beats Clovis Oncology on 8 of the 13 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
NLTX
Neoleukin Therapeutics
1.2$14.00-21.5%$537.41 million$25 million-5.24Analyst Upgrade
High Trading Volume
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$14.58-0.2%$529.23 million$1.52 million-7.76
Urogen Pharma logo
URGN
Urogen Pharma
1.6$25.36-0.6%$521.04 million$20,000.00-4.38
Athersys logo
ATHX
Athersys
2.0$2.69-0.7%$518.71 million$5.63 million-8.97
MIRM
Mirum Pharmaceuticals
1.6$20.15-1.3%$511.61 millionN/A-2.58Heavy News Reporting
Clovis Oncology logo
CLVS
Clovis Oncology
1.7$6.53-1.2%$508.31 million$143.01 million-0.91
Flexion Therapeutics logo
FLXN
Flexion Therapeutics
2.4$13.26-1.7%$504.75 million$72.96 million-3.50
Catalyst Pharmaceuticals logo
CPRX
Catalyst Pharmaceuticals
2.0$4.90-1.8%$497.43 million$102.31 million12.25Increase in Short Interest
IMRA
Passage Bio
1.6$28.46-0.4%$491.80 millionN/A0.00
Viking Therapeutics logo
VKTX
Viking Therapeutics
1.8$6.66-0.3%$488.60 millionN/A-15.86
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$18.06-1.7%$486.97 million$230,000.00-5.75
Zafgen logo
ZFGN
Zafgen
0.9$12.93-3.6%$484.49 millionN/A-13.47
Satsuma Pharmaceuticals logo
STSA
Satsuma Pharmaceuticals
1.5$27.25-0.2%$473.86 millionN/A-5.68
AC Immune logo
ACIU
AC Immune
1.3$6.87-2.8%$464.14 million$111.75 million-18.08Analyst Upgrade
Decrease in Short Interest
Merus logo
MRUS
Merus
2.0$15.47-2.3%$461.45 million$31.13 million-5.82Increase in Short Interest
BioSpecifics Technologies logo
BSTC
BioSpecifics Technologies
1.9$62.31-0.2%$458.16 million$38.19 million18.71
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.4$13.20-3.0%$448.02 million$6.83 million-9.85
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
1.9$4.49-0.9%$444.73 million$111.39 million-49.83
Beyondspring logo
BYSI
Beyondspring
1.2$14.77-0.3%$444.70 millionN/A-8.25
Geron logo
GERN
Geron
1.2$2.13-1.9%$441.20 million$460,000.00-5.46
Prothena logo
PRTA
Prothena
1.4$10.68-2.8%$438.21 million$810,000.00-5.29
DURECT logo
DRRX
DURECT
1.6$2.24-4.9%$425.38 million$29.56 million-18.67
XBiotech logo
XBIT
XBiotech
1.7$14.54-0.2%$418.61 millionN/A1.00Decrease in Short Interest
FULC
Fulcrum Therapeutics
1.4$17.85-4.4%$417.21 millionN/A-1.53
Puma Biotechnology logo
PBYI
Puma Biotechnology
1.4$10.53-1.1%$414.51 million$272.30 million-4.94
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.8$7.98-3.4%$408.20 million$4.23 million-4.07Analyst Downgrade
Aeglea Bio Therapeutics logo
AGLE
Aeglea Bio Therapeutics
2.1$8.86-2.3%$404.01 million$3.89 million-3.65
AVDR
Avedro
1.0$22.99-0.0%$402.79 million$27.67 million-1.28
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.53-2.8%$399.49 million$109.33 million-2.94
Avid Bioservices logo
CDMO
Avid Bioservices
1.6$7.02-2.6%$396.70 million$59.70 million-25.07Earnings Announcement
ORGO
Organogenesis
1.5$3.72-0.8%$394.72 million$260.98 million-8.65Analyst Downgrade
Decrease in Short Interest
Kamada logo
KMDA
Kamada
1.4$8.46-4.4%$393.11 million$127.19 million15.67
Ovid Therapeutics logo
OVID
Ovid Therapeutics
1.4$7.15-0.6%$392.56 millionN/A-4.80Increase in Short Interest
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$25.95-1.0%$388.72 million$9.64 million-4.41
CytomX Therapeutics logo
CTMX
CytomX Therapeutics
1.4$8.41-1.3%$386.21 million$57.49 million-4.98Increase in Short Interest
Heavy News Reporting
ANI Pharmaceuticals logo
ANIP
ANI Pharmaceuticals
1.6$30.89-3.2%$382.07 million$206.55 million-205.92Decrease in Short Interest
Heavy News Reporting
MannKind logo
MNKD
MannKind
1.9$1.74-2.9%$381.52 million$63.04 million-7.57Analyst Downgrade
TherapeuticsMD logo
TXMD
TherapeuticsMD
2.1$1.46-4.8%$377.64 million$49.65 million-1.92
MEI Pharma logo
MEIP
MEI Pharma
1.4$3.42-2.0%$369.93 million$4.91 million-11.40Analyst Report
High Trading Volume
Heavy News Reporting
Calithera Biosciences logo
CALA
Calithera Biosciences
1.6$5.15-1.7%$362.79 million$22.25 million-2.98Heavy News Reporting
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.5$5.09-2.0%$362.27 million$34.51 million-5.09High Trading Volume
Tocagen logo
TOCA
Tocagen
1.8$1.26-4.0%$360.22 million$40,000.00-0.53
Progenics Pharmaceuticals logo
PGNX
Progenics Pharmaceuticals
1.5$4.10-0.0%$355.05 million$34.99 million-5.32
Wave Life Sciences logo
WVE
Wave Life Sciences
1.7$9.73-1.8%$354.11 million$15.98 million-1.70Increase in Short Interest
Affimed logo
AFMD
Affimed
1.6$4.34-5.3%$348.42 million$23.96 million-6.38
Axovant Sciences logo
AXON
Axovant Sciences
1.3$2.75-0.4%$336.27 millionN/A-1.33
OSMT
Osmotica Pharmaceuticals
1.1$6.47-3.1%$333.34 million$240.03 million-1.27
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.5$1.92-0.5%$323.65 million$59.29 million-12.00
UROV
Urovant Sciences
1.2$10.50-4.2%$323.39 millionN/A-2.17Increase in Short Interest
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
2.0$8.70-8.4%$314.69 millionN/A-4.10High Trading Volume
Increase in Short Interest
This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.